EU-PEARL is a strategic partnership between the public and private sectors to shape the future of clinical trials. This innovative and challenging enterprise aims to create a framework for patient-centric integrated research platform (IRP) trials, through which novel techniques and treatments developed by multiple companies and organizations are tested in a platform trial.
To achieve this objective, EU-PEARL promotes cooperation amongst pharmaceutical companies, clinicians, patients, and researchers and encourages knowledge sharing and open discussion amongst all stakeholders, including regulators. This sustainable and reusable systematic approach to platform trials conceived to test multi-sourced compounds, is to be supported by a management structure designed by EU-PEARL which will be able to meet complex regulatory, ethical, legal, statistical, and data requirements.
EU-PEARL is also developing the specific IRPs frameworks for platform trials ready to operate in four disease areas still facing high unmet needs:
- Major Depressive Disorder (MDD),
- Tuberculosis (TB),
- Non-Alcoholic Steatohepatitis (NASH) and
- Neurofibromatosis (NF).
Public and private alliances have formed around these four disease areas and are now ready to support innovative clinical drug research of new techniques and treatments. EU-PEARL is set to create trial-ready clinical networks in these four disease areas, so that platform trials can be initiated shortly after the project is completed and funding secured.
“EU-PEARL has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853966-2. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA”.